Helo Corp.’s Patent Pending Side Sensor Enables Vascular Age Assessment on its Vyvo Life Watch 2
Back to Newsroom
Mentioned in this Article

Helo Corp.’s Patent Pending Side Sensor Enables Vascular Age Assessment on its Vyvo Life Watch 2

Wednesday, February 10, 2021 9:55 AM
Share this article now
Topic:
Company Update

SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2021 / Helo Corp. (OTC PINK:HLOC) ("Helo" or the "Company), a leading developer of wearable wireless devices embedded with Life Sensing TechnologyTM and dedicated to improving wellness worldwide, is pleased to announce that with its latest Vyvo Smart app update, it provides rapid, non-invasive Vascular Age assessment to all Vyvo Life Watch 2 users worldwide.

Vyvo's patent-pending side sensor captures high-quality fingertip photoplethysmogram (PPG) signals[1] on demand. Accelerated Plethysmography[2] (APG), which uses the second derivative of PPG waveform, is used to analyze the wearer's arterial stiffness and estimate their Vascular Age. The whole process takes less than a minute.

Figure: Vyvo Life Watch 2 with patent-pending side sensor and APG result displayed on the Vyvo Smart app.

Understanding the health of your cardiovascular system is paramount, because according to the World Health Organization, more people die annually from cardiovascular disease (CVD) than from any other cause, amounting to 17.9 million people or an estimated 31% of all deaths worldwide.

There are many ways to assess your Vascular Age, such as booking an appointment at a clinic where they can have advanced ultrasound technology, which can be used as an early biomarker of CVD and risk. Alternatively, your doctor may suggest one or more diagnostic tests, such as blood tests, Doppler ultrasound, Cardiac catheterization and angiogram, or other imaging tests. The challenge with CVD is that it is clinically silent (despite ongoing disease progression) so people at risk do not know to visit their doctor or clinic.

"You're as old as your arteries, which doesn't always equal the number of candles on your birthday cake." according to Harvard Medical School[3]. In young individuals, arteries are more elastic[4], but as we age, our arteries stiffen, and APG has been found to be useful for the estimation of risk of coronary heart disease in the general population[5].

Seán McVeigh, CEO of Helo Corp, stated, "APG technology is becoming more mainstream and it is already being used at clinics throughout the US, but so far, nobody has combined non-invasive Vascular Age assessment with the convenience of a wearable device. Our patent-pending side sensor has enabled this feature. Our users understand that our Life Watch 2 is not a medical device but it can provide a possible early warning and they should seek expert medical advice if they find that their Vascular Age is significantly greater than their chronological age."

About Helo Corp.

Helo Corp. (OTC:HLOC) is a wellness technology company in the digital health sharing economy using life watches and its proprietary bio-metrics data platform to encourage wellness-centered lifestyles and consumer data empowerment under the Vyvo brand. Our Life Sensing TechnologyTM uses state-of-the-art sensors, enhanced signal processing, and algorithms to collect and process specific bio-parameters for the user and Healthtech market. We incentivize our userbase with Vyvo Utility Tokens to continuously build up our shared bio-bank through self-tracking. Our two-sided data rich platform collects health data from the users, which we analyze and use AI to formulate customized and personalized user reports, user alerts, and NutraPak supplements, and our platform also presents Big Data opportunity for developers, medical research, and diagnostics.

Vyvo Life Watch 2 wearers can upgrade your App using Google Play or Apple's App Store.

For further information on Vyvo and Helo, please click on the links below:

https://www.vyvo.com andhttp://www.helocorp.com

Join Vyvo's Facebook Community https://www.facebook.com/VyvoCorp

Forward-Looking Statement

This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as may, "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," potential and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management's current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks is included in the Company's filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

Investors Contact:

[email protected]
650-646-2193
ClearThink
[email protected]

[1] Elgendi M. On the analysis of fingertip photoplethysmogram signals. Curr Cardiol Rev. 2012;8(1):14-25. doi:10.2174/157340312801215782.

[2] Takada H, Washino K, Harrell JS, Iwata H. Acceleration plethysmography to evaluate aging effect in cardiovascular system. Using new criteria of four wave patterns. Med Prog Technol. 1996-1997;21(4):205-10. PMID: 9110278.

[4] Mikael LR, Paiva AMG, Gomes MM, et al. Vascular Aging and Arterial Stiffness.Arq Bras Cardiol.2017; 109(3):253-258. doi:10.5935/abc.20170091.

[5] Otsuka T, Kawada T, Katsumata M, Ibuki C. Utility of second derivative of the finger photoplethysmogram for the estimation of the risk of coronary heart disease in the general population. Circ J. 2006 Mar;70(3):304-10. doi: 10.1253/circj.70.304. PMID: 16501297.

SOURCE: Helo Corp. ​​​​​​​

Helo Corp.
Back to Newsroom
{{msgBox.title}}

that

Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions